ArticleAntimicrobial agents and chemotherapy2016
Sustained Nitric Oxide-Releasing Nanoparticles Induce Cell Death in Candida albicans Yeast and Hyphal Cells, Preventing Biofilm Formation In Vitro and in a Rodent Central Venous Catheter Model.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Nitric Oxide-Releasing Microparticles: A Novel Treatment for Onychomycosis.Molecular pharmaceutics · 2025Article
- Combating Concomitant Bacterial and Fungal Infections via Codelivery of Nitric Oxide and Fluconazole.ACS applied materials & interfaces · 2025Article
- Investigation of the susceptibility of clinical infection loads to nitric oxide antibacterial treatment.Nitric oxide : biology and chemistry · 2025Article
- Impact of Nitric Oxide-Release Kinetics on Antifungal Activity.Journal of fungi (Basel, Switzerland) · 2024Article
- Micro- and nanoparticles as platforms for the treatment of fungal infections: present and future perspectives.Future microbiology · 2023Article
- Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosisAntimicrobial agents and chemotherapy · 2023Article
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- 3-Hydroxy coumarin demonstrates anti-biofilm and anti-hyphal efficacy against Candida albicans via inhibition of cell-adhesion, morphogenesis, and virulent genes regulation.Scientific reports · 2023Article
- Emerging and future strategies in the management of recalcitrant Candida auris.Medical mycology · 2022Review
- Recent Developments in Nitric Oxide Donors and Delivery for Antimicrobial and Anti-Biofilm Applications.Molecules (Basel, Switzerland) · 2022Review
- Intestinal Infection ofFrontiers in microbiology · 2021Review
- Mechanistic Understanding ofFrontiers in microbiology · 2021Review
- NOJournal of fungi (Basel, Switzerland) · 2020Article
- The potential of respiration inhibition as a new approach to combat human fungal pathogens.Current genetics · 2019Review
- Dietary Nitrite Drives Disease Outcomes in Oral Polymicrobial Infections.Journal of dental research · 2019Article
- Article
- Nitric oxide increases biofilm formation inBiotechnology for biofuels · 2019Article
- Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections.Antimicrobial agents and chemotherapy · 2018Article
- Guidelines and recommendations on yeast cell death nomenclature.Microbial cell (Graz, Austria) · 2018Review
- Targeting microbial biofilms: current and prospective therapeutic strategies.Nature reviews. Microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Candida albicansis a leading nosocomial pathogen. Today, candidal biofilms are a significant cause of catheter infections, and such infections are becoming increasingly responsible for the failure of medical-implanted devices.C. albicansforms biofilms in which fungal cells are encased in an autoproduced extracellular polysaccharide matrix. Consequently, the enclosed fungi are protected from antimicrobial agents and host cells, providing a unique niche conducive to robust microbial growth and a harbor for recurring infections. Here we demonstrate that a recently developed platform comprised of nanoparticles that release therapeutic levels of nitric oxide (NO-np) inhibits candidal biofilm formation, destroys the extracellular polysaccharide matrices of mature fungal biofilms, and hinders biofilm development on surface biomaterials such as the lumen of catheters. We found NO-np to decrease both the metabolic activity of biofilms and the cell viability ofC. albicansin vitroandin vivo Furthermore, flow cytometric analysis found NO-np to induce apoptosis in biofilm yeast cellsin vitro Moreover, NO-np behave synergistically when used in combination with established antifungal drug therapies. Here we propose NO-np as a novel treatment modality, especially in combination with standard antifungals, for the prevention and/or remediation of fungal biofilms on central venous catheters and other medical devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.